The high throughput screening market was valued at US$ 28,255.71 million in 2028 from US$ 15,997.47 million in 2021. The market is estimated to grow with a CAGR of 8.5% from 2021 to 2028.
Factors such as the increase in investment in research and development by the pharmaceutical and biotechnology industry and the introduction of technologically advanced products in the high throughput screening market are expected to boost the market growth over the years. However, the high cost of high-throughput screening, lack of trained professionals, and complexity in assay development are likely to hamper the market’s growth in the coming years. High-throughput screening (HTS) is a drug discovery process that allows automated testing of many chemical and biological compounds for a specific biological target.High-throughput screening methods are extensively used in the pharmaceutical industry, leveraging robotics and automation to quickly test the biological or biochemical activity of a large number of molecules, usually drugs.
They accelerate target analysis, as large-scale compound libraries can soon be screened cost-effectively. HTS is a valuable tool for assessing, for instance, pharmacological targets, pharmacologically profiling agonists, and antagonists for receptors (such as GPCRs) and enzymes.
The global high throughput screening market is segmented based on product and service, technology, application, and end-user.Based on product and service, the high throughput screening market is categorized into consumables, instruments, accessories, software, services.
In 2021, the consumables segment held the largest share of the market by product and service.The same high throughput screening market segment is also expected to witness the fastest CAGR from 2021 to 2028.
Based on technology, the high throughput screening market has been segmented into cell-based assays, lab-on-a-chip, ultra-high-throughput screening, bioinformatics, label-free technology. In 2021, the cell-based assays segment held the largest share of the market by technology.
In contrast, the lab-on-a-chip segment is expected to grow at the fastest CAGR during the forecasted period.Based on application, the high throughput screening market has been segmented into drug discovery, biochemical screening, life sciences research, other applications.
In 2021, the drug discovery segment held the largest share of the market, by application and the segment is expected to grow at the fastest CAGR during the forecasted period.Based on end-user, the high throughput screening market has been segmented into pharmaceutical and biotechnology companies, academic and government institutes, contract research organizations (CRO), and others.
In 2021, the pharmaceutical and biotechnology companies segment held the largest share of the market by technology. The contract research organizations (CRO) segment is expected to grow at the fastest CAGR during the forecast period.
Contract research organizations, OEMs, and manufacturing organizations are among the primary and secondary sources referred to while preparing the high throughput screening market report.
Our reports have been used by over 10K customers, including:
The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026. Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research...
The global ATP assays market is projected to reach USD 412 million by 2027 from USD 276 million in 2022, at a CAGR of 8.4%. The growth of this market can largely be attributed to the increasing food safety concerns, growing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology...
The global liquid handling systems market is expected to reach USD 5.1 billion by 2026 from USD 4.0 billion in 2021, at a CAGR of 5.1% during the forecast period. The growth of this market is majorly driven by industrial growth in the pharma-biotech sector, rising R&D expenditure by biopharma companies, and growing life science research, supported...
The global IVD contract research organization market is expected to grow from US$ 4,738.79 million in 2021 to US$ 8,019.53 million by 2028; it is estimated to grow at a CAGR of 7.8% from 2021 to 2028. The rising prevalence of infectious diseases increases the demand for IVD and clinical trials along with new product launches, which...
The global CDMO market is estimated to reach US$246.6 billion in 2026, growing at a CAGR of 9.31%, for the period spanning 2022-2026. The factors such as increasing per capita disposable income, increasing global healthcare expenditure, rising aging population, increasing R&D spending, growing number of new drugs, rise in investments and strategic...
The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages...
Benign Prostatic Hyperplasia (Womens and Male Health) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2021, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.Benign...
The contract research organization (CRO) market is expected to reach US$ 88,835.19 million in 2028 from US$ 50,093.56 million in 2021; it is expected to grow at a CAGR of 8.5% from 2021 to 2028. The growth of the market is primarily attributed to the surge in R&D expenditures and outsourcing activities, and rise in the number of clinical...
The protein binding assay market is expected to reach US$ 694.63 million by 2028 from US$ 340.14 million in 2021; it is estimated to grow at a CAGR of 10.7% from 2021 to 2028. Surge in drug discovery activities and growing need to reduce the costs of drug discovery and development are among key factors driving the market growth. However, challenges...
Pharmaceutical
Drug Development
Infectious Disease
World
APAC
Pharmaceutical R&D Expenditure
Prescription Drug Sales
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.